» Articles » PMID: 28861502

Cannabinoids in Parkinson's Disease

Overview
Specialty Pharmacology
Date 2017 Sep 2
PMID 28861502
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The endocannabinoid system plays a regulatory role in a number of physiological processes and has been found altered in different pathological conditions, including movement disorders. The interactions between cannabinoids and dopamine in the basal ganglia are remarkably complex and involve both the modulation of other neurotransmitters (γ-aminobutyric acid, glutamate, opioids, peptides) and the activation of different receptors subtypes (cannabinoid receptor type 1 and 2). In the last years, experimental studies contributed to enrich this scenario reporting interactions between cannabinoids and other receptor systems (transient receptor potential vanilloid type 1 cation channel, adenosine receptors, 5-hydroxytryptamine receptors). The improved knowledge, adding new interpretation on the biochemical interaction between cannabinoids and other signaling pathways, may contribute to develop new pharmacological strategies. A number of preclinical studies in different experimental Parkinson's disease (PD) models demonstrated that modulating the cannabinoid system may be useful to treat some motor symptoms. Despite new cannabinoid-based medicines have been proposed for motor and nonmotor symptoms of PD, so far, results from clinical studies are controversial and inconclusive. Further clinical studies involving larger samples of patients, appropriate molecular targets, and specific clinical outcome measures are needed to clarify the effectiveness of cannabinoid-based therapies.

Citing Articles

Exploring The Contours: Navigating Cannabis Use Among Older Adults.

Shin Y, Moussa M, Akwe J J Brown Hosp Med. 2025; 3(3):120951.

PMID: 40026396 PMC: 11864428. DOI: 10.56305/001c.120951.


mFusion: a multiscale fusion method bridging neuroimages to genes through neurotransmissions in mental health disorders.

Cao L, Wang Z, Yuan Z, Luo Q Commun Biol. 2024; 7(1):1699.

PMID: 39719509 PMC: 11668864. DOI: 10.1038/s42003-024-07404-x.


CBD's potential impact on Parkinson's disease: An updated overview.

Hafida E, Rachid S, Halima G, Najib K Open Med (Wars). 2024; 19(1):20241075.

PMID: 39479465 PMC: 11524397. DOI: 10.1515/med-2024-1075.


The Use of Compounds Derived from in the Treatment of Epilepsy, Painful Conditions, and Neuropsychiatric and Neurodegenerative Disorders.

Stasilowicz-Krzemien A, Nogalska W, Maszewska Z, Maleszka M, Dobron M, Szary A Int J Mol Sci. 2024; 25(11).

PMID: 38891938 PMC: 11171823. DOI: 10.3390/ijms25115749.


Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.

Blebea N, Pricopie A, Vlad R, Hancu G Int J Mol Sci. 2024; 25(8).

PMID: 38673788 PMC: 11050509. DOI: 10.3390/ijms25084204.


References
1.
Lovinger D . Presynaptic modulation by endocannabinoids. Handb Exp Pharmacol. 2007; (184):435-77. DOI: 10.1007/978-3-540-74805-2_14. View

2.
Huestis M . Human cannabinoid pharmacokinetics. Chem Biodivers. 2007; 4(8):1770-804. PMC: 2689518. DOI: 10.1002/cbdv.200790152. View

3.
Chung H, Ge W, Qian X, Wiser O, Jan Y, Jan L . G protein-activated inwardly rectifying potassium channels mediate depotentiation of long-term potentiation. Proc Natl Acad Sci U S A. 2009; 106(2):635-40. PMC: 2613041. DOI: 10.1073/pnas.0811685106. View

4.
Garcia-Arencibia M, Ferraro L, Tanganelli S, Fernandez-Ruiz J . Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neurosci Lett. 2008; 438(1):10-3. DOI: 10.1016/j.neulet.2008.04.041. View

5.
Pisani A, Fezza F, Galati S, Battista N, Napolitano S, Finazzi-Agro A . High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol. 2005; 57(5):777-9. DOI: 10.1002/ana.20462. View